+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Preventive Medicine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 140 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294783
The preventive medicine market size was valued at USD 477.29 billion in 2026 and is estimated to grow from USD 503.26 billion in 2027 to reach USD 655.87 billion by 2032, at a CAGR of 5.44% during the forecast period (2027-2032). This report is Segmented by Prevention Type (Primary Prevention and More), Product Type (Screening & Early Detection and More), Application (Cardiovascular Disease Prevention and More), End User (Hospitals and Primary Care Centers and More), Delivery Mode (In-Person Services and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Preventive Medicine Market Trends and Insights

Rising Chronic Disease Burden and Avoidable Hospital Utilization

The rising burden of hypertension, prediabetes, dyslipidemia, and obesity is increasing demand for earlier clinical intervention.Health systems are prioritizing the identification of cardiometabolic risk before complications require higher-cost care, supporting demand for early-intervention solutions in the Preventive Medicine Market. CMS introduced the ACCESS model in July 2026 to support outcome-aligned care for early cardiometabolic, musculoskeletal, and behavioral health conditions. The model links payment to outcomes such as blood pressure, HbA1c, weight, and cholesterol management. Research published in 2025 noted that polygenic scores and AI-supported approaches improve individualized cardiovascular risk assessment, supporting expanded screening and prevention for working-age adults previously considered low risk.

Expansion of Adult, Maternal, and Life-Course Immunization

Adult and maternal immunization is becoming a larger component of preventive care delivery. The Rise to Immunize campaign reached 35.7 million adult vaccines administered over five years in 2026. Participating organizations recorded a 21.2% improvement in zoster vaccination and a 6.1% increase in RSV vaccination over one year. National purchasing decisions also influence the market by expanding vaccine access across age groups. In August 2026, New Zealand’s Pharmac finalized agreements covering 17 vaccines and one diagnostic test, including the replacement of Prevenar 13 with Prevenar 20 as the funded pneumococcal vaccine.

Prevention-First Economics Versus Short-Term Provider Incentives

Preventive programs often require upfront investment, while financial benefits accrue over several years. This timing gap can discourage provider investment when reimbursement remains linked to short service cycles. Prevention remains financially fragile, even within value-based care models, while treatment services typically generate more predictable payments. This challenge affects primary care practices, laboratories, and digital health suppliers that require multiyear reimbursement commitments. Broader adoption of outcome-aligned payment models could improve financial certainty, although implementation remains uneven across the preventive medicine market.

Other drivers and restraints analyzed in the detailed report include:

  1. Reimbursement And Value-Based Care
  2. AI-Enabled Screening and Risk Stratification
  3. Unequal Access From Insurance, Income, Rurality, and Digital Exclusion

Segment Analysis

Primary prevention accounted for 34.67% of the preventive medicine market share in 2026, supported by vaccination, broad screening initiatives, and lifestyle programs. National immunization systems and employer wellness budgets provide established delivery channels. These services are widely available through primary care settings, pharmacies, workplaces, and public health providers, supporting stable demand across population groups. Secondary prevention is projected to grow at a 7.28% CAGR through 2032, driven by increased use of risk scoring, point-of-care testing, and early intervention for individuals without diagnosed diseases.

Secondary prevention is becoming more personalized as digital tools combine clinical records, biometrics, and risk factors. Genomics, AI, and wearable devices are strengthening preventive care across the traditional prevention framework. This approach enables providers to identify individuals requiring closer monitoring before symptoms emerge. Tertiary prevention and recurrence reduction remain important in oncology, cardiovascular care, and metabolic health, linking long-term monitoring with efforts to prevent complications or recurrence.

Screening and early detection accounted for 44.93% of revenue in 2026. The segment benefits from established clinical pathways, public health programs, and the wider availability of diagnostic technologies. Abbott launched its SimpleScreen CRC blood test in the United States in September 2026 for adults aged 45 years and older who are at average risk of colorectal cancer. Medicare covers the test with no out-of-pocket cost for eligible patients.

Broader reimbursement and less invasive testing can increase participation among individuals who do not complete conventional screening. These factors support screening's leading position in the preventive medicine market. Wellness and lifestyle interventions are forecast to grow at an 8.12% CAGR through 2032. Employers and payers are expanding programs that address nutrition, physical activity, stress, and behavior before health conditions worsen. The category benefits from digital coaching, virtual care, and devices that support regular engagement. Vaccination and immunization remain major service areas because they are embedded in national schedules and community delivery channels.

Complete Report Scope:

  • By Prevention Type
    • Primary Prevention
    • Secondary Prevention
    • Tertiary Prevention and Recurrence Reduction
  • By Product and Service Type
    • Screening & Early Detection
    • Vaccination & Immunization
    • Preventive Drug Therapies
    • Wellness & Lifestyle Interventions
    • Digital Health & Remote Monitoring Services
    • Others
  • By Application
    • Cardiovascular Disease Prevention
    • Cancer Prevention
    • Diabetes and Metabolic Disease Prevention
    • Infectious Disease Prevention
    • Respiratory Disease Prevention
    • Maternal, Newborn and Child Health Prevention
    • Neurological Disease and Cognitive-Decline Prevention
    • Other Applications
  • By End User
    • Hospitals and Primary Care Centers
    • Diagnostic Laboratories and Screening Centers
    • Ambulatory and Specialty Care Centers
    • Government and Public Health Agencies
    • Corporate and Workplace Wellness Providers
    • Home Healthcare and Direct-to-Consumer Channels
    • Other End Users
  • By Delivery Mode
    • In-Person Services
    • Telemedicine and Remote Care
    • Mobile Health Applications
    • At-Home Collection and Testing
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 38.88% of revenue in 2026, supported by mature reimbursement frameworks for preventive services, high screening utilization, and a large employer-sponsored health benefits base. CMS expanded its focus on technology-enabled, outcome-aligned care through the ACCESS model. The CY 2026 Medicare Physician Fee Schedule also added a semiannual physical activity and nutrition risk assessment code. These developments support screening, risk assessment, and regular follow-up. Abbott’s SimpleScreen CRC launch demonstrates how Medicare coverage supports the adoption of blood-based screening formats. Canada is expanding digital prevention tools through provincial health systems, while Mexico remains focused on immunization and maternal health coverage. Access disparities between insured urban populations and underserved rural communities remain a key challenge across the region.

Asia-Pacific is forecast to grow at a CAGR of 9.88% through 2032, driven by demographic pressures, government digitalization initiatives, national immunization programs, and rising consumer awareness. Japan’s worker-focused metabolic screening system generates recurring demand for diagnostics and monitoring among its large adult population. South Korea’s public support for senior wearables demonstrates how government programs encourage home health monitoring. In India, Plum’s INR 2 billion, equivalent to USD 25 million, commitment in July 2025 indicates growing employer demand for preventive benefits. China, India, South Korea, Japan, Australia, and New Zealand have distinct payment and regulatory systems, making local partnerships important. New Zealand’s 2026 vaccine supply agreements demonstrate how national purchasing decisions influence preventive service availability. The preventive medicine market size in Asia-Pacific will be shaped by the ability of digital health programs to reach rural populations as well as residents of major cities.

Europe has organized screening programs, strong preventive care policies, and an established digital health regulatory environment. However, differences in reimbursement and implementation across countries moderate regional growth. The European IVDR framework supports consistent requirements for in vitro diagnostics and related self-collection tools. Roche’s CE-marked kidney algorithm demonstrates the region’s focus on regulated, AI-supported risk assessment. The Middle East and Africa have significant unmet needs for preventive care, particularly in areas with limited screening capacity or digital access. South America is seeing increased interest in AI and digital health, although service quality depends on locally representative data. A 2025 study identified lower AI performance among low-socioeconomic groups in Latin America and the Caribbean. Providers that adapt their models to local clinical data and care infrastructure will have stronger prospects across these diverse regions.



List of Companies Covered in this Report:

  1. Abbott Laboratories
  2. AstraZeneca
  3. Beckton Dickinson
  4. bioMérieux
  5. Danaher
  6. Dexcom
  7. Eli Lilly and Company
  8. Roche
  9. GE HealthCare Technologies Inc.
  10. GlaxoSmithKline
  11. Illumina
  12. Johnson & Johnson
  13. Koninklijke Philips
  14. Medtronic
  15. Merck
  16. Pfizer
  17. Quest Diagnostics
  18. Sanofi
  19. Siemens Healthineers
  20. Thermo Fisher Scientific

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Chronic Disease Burden and Avoidable Hospital Utilization
4.2.2 Expansion of Adult, Maternal and Life-Course Immunization
4.2.3 Reimbursement and Value-Based Care Incentives for Early Detection
4.2.4 AI-Enabled Screening and Risk Stratification
4.2.5 Underdiagnosed Cardiometabolic Risk in Previously Healthy Populations
4.2.6 Interoperable Home Monitoring and Consumer Health Data
4.3 Market Restraints
4.3.1 Prevention-First Economics Versus Short-Term Provider Incentives
4.3.2 Unequal Access From Insurance, Income, Rurality and Digital Exclusion
4.3.3 False Positives, Overdiagnosis and Patient Trust Risk
4.3.4 Fragmented Data Governance and Cybersecurity Liability
4.4 Value/Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
5.1 By Prevention Type
5.1.1 Primary Prevention
5.1.2 Secondary Prevention
5.1.3 Tertiary Prevention and Recurrence Reduction
5.2 By Product and Service Type
5.2.1 Screening & Early Detection
5.2.2 Vaccination & Immunization
5.2.3 Preventive Drug Therapies
5.2.4 Wellness & Lifestyle Interventions
5.2.5 Digital Health & Remote Monitoring Services
5.2.6 Others
5.3 By Application
5.3.1 Cardiovascular Disease Prevention
5.3.2 Cancer Prevention
5.3.3 Diabetes and Metabolic Disease Prevention
5.3.4 Infectious Disease Prevention
5.3.5 Respiratory Disease Prevention
5.3.6 Maternal, Newborn and Child Health Prevention
5.3.7 Neurological Disease and Cognitive-Decline Prevention
5.3.8 Other Applications
5.4 By End User
5.4.1 Hospitals and Primary Care Centers
5.4.2 Diagnostic Laboratories and Screening Centers
5.4.3 Ambulatory and Specialty Care Centers
5.4.4 Government and Public Health Agencies
5.4.5 Corporate and Workplace Wellness Providers
5.4.6 Home Healthcare and Direct-to-Consumer Channels
5.4.7 Other End Users
5.5 By Delivery Mode
5.5.1 In-Person Services
5.5.2 Telemedicine and Remote Care
5.5.3 Mobile Health Applications
5.5.4 At-Home Collection and Testing
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 AstraZeneca PLC
6.3.3 Becton, Dickinson and Company
6.3.4 bioMerieux SA
6.3.5 Danaher Corporation
6.3.6 DexCom Inc.
6.3.7 Eli Lilly and Company
6.3.8 F. Hoffmann-La Roche Ltd
6.3.9 GE HealthCare Technologies Inc.
6.3.10 GSK PLC
6.3.11 Illumina Inc.
6.3.12 Johnson & Johnson
6.3.13 Koninklijke Philips N.V.
6.3.14 Medtronic PLC
6.3.15 Merck & Co. Inc.
6.3.16 Pfizer Inc.
6.3.17 Quest Diagnostics Incorporated
6.3.18 Sanofi
6.3.19 Siemens Healthineers AG
6.3.20 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • DexCom Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc.
  • GSK PLC
  • Illumina Inc.
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Sanofi
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.